Jay Feingold

ChemistryMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia”.

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia

Blood Advances(2020)10.1182/bloodadvances.2019000767

N/A

2.9DataRank · unranked

56 citations

Wendy Stock, Amer M. Zeidan, Ehab Atallah, James McCloskey, Leonard T. Heffner +11 more

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study

The Lancet Haematology(2021)10.1016/s2352-3026(21)00103-4

N/A

2.5DataRank · unranked

86 citations

Graham P. Collins, Paolo F. Caimi, Felipe Samaniego, Alexander I. Spira, Andrew Davies +13 more